XTLB

XTL Biopharmaceuticals
XTLB

1 day

0.00%

5 days

0.00%

1 month

0.00%

3 months

0.00%

6 months

0.00%

Year to date

0.00%

1 year

0.00%

5 years

0.00%

10 years

0.00%

About: XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Employees: 4

Healthcare Biotechnology

0

Funds holding %

of 7,407 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 3 [Q3] → 3 (+0) [Q4]

0% less ownership

Funds ownership: 0.02% [Q3] → 0.02% (-0%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

17% less capital invested

Capital invested by funds: $556K [Q3] → $463K (-$93.6K) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XTLB.

See Analyst Rankings

Financial journalist opinion

XTL Names Mr. Noam Band as its New Chief Executive Officer

Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company's new Chief Executive Officer.

XTL Names Mr. Noam Band as its New Chief Executive Officer

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 Million RAMAT GAN, ISRAEL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- August 14, 2024, XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has completed the acquisition of THE SOCIAL PROXY Ltd.

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

XTL Entered Definitive Agreement to Acquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, June 05, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has entered into a definitive share purchase agreement with the current shareholders of THE SOCIAL PROXY Ltd.

XTL Entered Definitive Agreement to Acquire The Social Proxy

XTL To Aquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd.

XTL To Aquire The Social Proxy

See News Rankings

Charts implemented using Lightweight Charts™